Contact
searchSearch
HMP Global
Login

Biomarker Testing Topic Center

Featured

Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Review
NGS Testing in Non–Small Cell Lung Cancer
09/19/2023
Winston Wong, PharmD; Gordon Kuntz
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon...
09/19/2023
Journal of Clinical Pathways
NGS Institute
The NGS Institute: Advancing the Appropriate Use of Biomarker Testing
02/06/2023
Gordon Kuntz
The NGS Institute is a trusted resource for curated, practical information on biomarker and next-generation sequencing testing. This article outlines the aim the Institute has to play a role in facilitating the integration of genomic-level...
The NGS Institute is a trusted resource for curated, practical information on biomarker and next-generation sequencing testing. This article outlines the aim the Institute has to play a role in facilitating the integration of genomic-level...
The NGS Institute is a trusted...
02/06/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Dan Rhodes, PhD
Podcasts
Episode 5: Cancer Genomics and Genetic Testing in the Era of Precision Medicine: What is a Precision Model of Care?
10/31/2022
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes,...
10/31/2022
Journal of Clinical Pathways
News
State Legislative Trends in Biomarker Testing
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
Mismatch Repair/Microsatellite Instability Biomarker Testing Utilization in Advanced Colorectal Cancer
09/20/2022
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study...
09/20/2022
Journal of Clinical Pathways
News
Factors Associated With Receipt of Biomarker Testing Among Patients With Metastatic Colorectal Cancer
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in...
09/20/2022
Journal of Clinical Pathways
News
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers
09/19/2022
Craig Ostroff
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study...
09/19/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways

News

News
State Legislative Trends in Biomarker Testing
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
Mismatch Repair/Microsatellite Instability Biomarker Testing Utilization in Advanced Colorectal Cancer
09/20/2022
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study...
09/20/2022
Journal of Clinical Pathways
News
Factors Associated With Receipt of Biomarker Testing Among Patients With Metastatic Colorectal Cancer
09/20/2022
Yvette C. Terrie, BS Pharm, RPh
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in...
09/20/2022
Journal of Clinical Pathways
News
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers
09/19/2022
Craig Ostroff
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study...
09/19/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
Ellen Kurek
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
News
Outcomes of Patients With NSCLC Participating in Medicaid vs Commercial Insurance
06/12/2022
Ellen Kurek
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study...
06/12/2022
Journal of Clinical Pathways
News
Artificial Intelligence-Powered Spatial Analysis of TILs Predicts Treatment Outcomes With ICIs in NSCLC
05/16/2022
Ellen Kurek
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
Biomarker Testing Rates and Turnaround Times for Patients With NSCLC Receiving First-Line Therapy in The US Oncology Network
04/01/2022
Janelle Bradley
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways
News
Evolving Treatment Patterns in HCC Reflect Expanding Role of Immunotherapy
05/27/2026
Rebecca Amrick
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving treatment patterns for hepatocellular carcinoma (HCC) shows the emergence of several new first-line therapies and the decline of second-line therapies, highlighting efforts to optimize treatment sequencing to improve...
An overview of evolving...
05/27/2026
Journal of Clinical Pathways
News
Type 2 Diabetes Prevention May Reduce the Risk of Diffuse Large B-cell Lymphoma and Multiple Myeloma
05/26/2026
Rebecca Amrick
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations between type 2 diabetes (T2D) and non-Hodgkin lymphoma instead found a positive link between T2D and the risk of multiple myeloma and diffuse large B-cell lymphoma, suggesting that T2D prevention may reduce...
A study looking for associations...
05/26/2026
Journal of Clinical Pathways
News
Guideline-Based Pathways Could Streamline Prior Authorization Processes
05/21/2026
Rebecca Amrick
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have the potential to decrease administrative burdens by streamlining prior authorization approvals.
Guideline-based pathways have...
05/21/2026
Journal of Clinical Pathways
News
Higher Radon Levels Connected to Increased Risk of Ovarian Cancer in Postmenopausal Women
05/21/2026
Rebecca Amrick
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds that exposure to higher levels of radon could increase the risk of ovarian cancer, opening a possibility for ovarian cancer prevention.
An observational study finds...
05/21/2026
Journal of Clinical Pathways
News
Improving Geriatric Care for Older Patients With MM
05/20/2026
Rebecca Amrick
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have identified key challenges and gaps in care for older patients in North America with multiple myeloma (MM) and made recommendations for improving care and education in geriatric oncology.
Medical professionals have...
05/20/2026
Journal of Clinical Pathways
News
High-Risk Individuals Delay Lung Cancer Screenings Until Eligible Despite Expanded Medicare Access
05/18/2026
Rebecca Amrick
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s nearly-universal access for people 65 and older shows evidence of patients delaying lung cancer screenings until they are eligible for coverage, raising concerns about health care access and patient outcomes.
A study of Medicare’s...
05/18/2026
Journal of Clinical Pathways
News
Dexamethasone Prophylaxis is a Promising Intervention Therapy for Patients With RRMM Receiving Cilta-Cel
05/15/2026
Rebecca Amrick
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows potential in reducing absolute lymphocyte count (ALC) expansion and mitigating immune-related adverse events for patients with relapsed or refractory multiple myeloma (RRMM) being treated with ciltacabtagene...
Dexamethasone prophylaxis shows...
05/15/2026
Journal of Clinical Pathways
News
HCC Incidence Higher in Rural Populations Due to Changing Risk Factors and Access Barriers
05/15/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC) incidence and mortality disproportionately affect rural and urban populations, reflecting the need for targeted strategies to improve prevention and access to specialty care.
Hepatocellular carcinoma (HCC)...
05/15/2026
Journal of Clinical Pathways
News
A New Clinic in Minneapolis is Expected to Expand Health Care Access to Low-Income Populations
05/12/2026
Rebecca Amrick
A new clinic in Minnesota has recently opened to expand care access and treat low-income populations in Southside Minneapolis.
A new clinic in Minnesota has recently opened to expand care access and treat low-income populations in Southside Minneapolis.
A new clinic in Minnesota has...
05/12/2026
Journal of Clinical Pathways
News
Study Finds Comparable Outcomes for Regorafenib and FTD/TPI Sequencing in Metastatic Colorectal Cancer
05/12/2026
Rebecca Amrick
A real-world study suggests that the sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) may have minimal impact on survival outcomes in patients with metastatic colorectal cancer, underscoring the need for personalized treatment...
A real-world study suggests that the sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) may have minimal impact on survival outcomes in patients with metastatic colorectal cancer, underscoring the need for personalized treatment...
A real-world study suggests that...
05/12/2026
Journal of Clinical Pathways

Video

Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Nicholas Robert, MD
Videos
Identifying Predictors of Biomarker Testing in Metastatic Non-Small Cell Lung Cancer
07/05/2022
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses...
07/05/2022
Journal of Clinical Pathways
Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
04/27/2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS,...
04/27/2021
Journal of Clinical Pathways
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
12/04/2025
Houda Hachad, PharmD
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing...
12/04/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange

From the Journal

Trending From ACCC
ACCC Releases Biomarker Testing Implementation Roadmap
11/16/2021
The ACCC released an innovative learning tool that helps multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
The ACCC released an innovative learning tool that helps multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
The ACCC released an innovative...
11/16/2021
Journal of Clinical Pathways
From the Field
Shining a Light on Payer Management in Medical-Benefit Oncology: A Call for Action to Prioritize Patient Care
04/18/2026
Lucio Gordan, MD; Kiana Mehring, MBA, PPMC; David T. Wenk, MD; Josh Eaves; Ryan Ciarrocchi
This study reveals how increasing payer control over oncology treatments is driving delays and administrative burden, undermining evidence-based, physician-led care and timely patient access.
This study reveals how increasing payer control over oncology treatments is driving delays and administrative burden, undermining evidence-based, physician-led care and timely patient access.
This study reveals how...
04/18/2026
Journal of Clinical Pathways
Research Reports
An Oncology Provider-Driven Model to Implement Germline Genetic Testing Among Diverse Patients With Advanced Prostate Cancer
08/15/2025
Lisa Nuccio, MSN, FNP-C; Kirsten Drabek, BS; Neha Hippalgaonkar, MD; Aseem Tiwari, MPH, MD, MBBS; Vivian Pan, MS, PhD; Kent Hoskins, MD; Pamela Ganschow, MD; Tara Maga, PhD, MS; Lara Balay, MS Ed, MS, CGC; Karine Tawagi, MD; Natalie Reizine, MD
In this study, researchers examine the clinical implementation of an oncology-directed model of delivering guideline-concordant germline genetic testing in patients living with and receiving standard-of-care treatment for advanced prostate...
In this study, researchers examine the clinical implementation of an oncology-directed model of delivering guideline-concordant germline genetic testing in patients living with and receiving standard-of-care treatment for advanced prostate...
In this study, researchers...
08/15/2025
Journal of Clinical Pathways
From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2025
Anna Bolha, MPAS, PA; Rebecca Maniago, PharmD, BCOP; Nina Sardesh; Taylor Dias-Foundas; James Roose, MA; Colin Harvey; Marcello Ricottone; Eric Weber; Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC; Brian Patrick Mulherin, MD; Andrew Hertler, MD, FACP; James Hamrick, MD, MPH
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2025
Journal of Clinical Pathways
Research Reports
Oncology Pathways Drive Adoption of High-Quality Treatment Regimens and Deliver Drug Cost Savings
08/15/2025
Kathryn Christensen, MD, MS; Timothy Dollear, MD, MS; Rama Al Ghannam, PharmD; Eric Gratias, MD, FAAP; Robinson Ortiz, MD; Stephen Hamilton, MD
Kathryn Christensen, MS, and colleagues share the initial results of the launch of Cigna and eviCore Healthcare’s Oncology Value-based Pathways program.
Kathryn Christensen, MS, and colleagues share the initial results of the launch of Cigna and eviCore Healthcare’s Oncology Value-based Pathways program.
Kathryn Christensen, MS, and...
08/15/2025
Journal of Clinical Pathways
From the Field
Operationalizing Weight-Based Dosing of Pembrolizumab: Opportunities and Challenges
08/15/2025
Samyukta Mullangi, MD, MBA; Alphan Kirayoglu, MA; Amila Patel, PharmD; Robert J. Green, MD, MSCE; Keshav Goel, MS; James Gilmore, PharmD; Stephen Garrel Divers, MD
To curb the high cost of cancer care driven by flat-dose pricing of drugs like pembrolizumab, the American Oncology Network has implemented a suite of technological and workflow innovations that increased weight-based dosing, offering a...
To curb the high cost of cancer care driven by flat-dose pricing of drugs like pembrolizumab, the American Oncology Network has implemented a suite of technological and workflow innovations that increased weight-based dosing, offering a...
To curb the high cost of cancer...
08/15/2025
Journal of Clinical Pathways
Research Reports
Lessons Learned From the Development and Implementation of a Shared Decision-Making Process for Severe Stroke Using a Digital Communication Platform
04/15/2025
Akila Visvanathan, PhD; Sarah Morton, PhD; Allan Macraild, MSc; Polly Black, MSc; Sophie Gilbert, MSc; Mark Barber, MD; Martin Dennis, MD; Richard O'Brien, MD; Gillian Mead, MD
This study explored the use of a digital platform to support shared decision-making in a stroke unit, revealing critical barriers that must be addressed to improve patient-centered outcomes.
This study explored the use of a digital platform to support shared decision-making in a stroke unit, revealing critical barriers that must be addressed to improve patient-centered outcomes.
This study explored the use of a...
04/15/2025
Journal of Clinical Pathways
From the Field
Turning Pathways on Their Head: Deimplementation of Low-Value Treatment Regimens
04/15/2025
Sang Chau, PharmD, BCOP; Amy VanGalder, PharmD, BCOP; Garrick Wong, PharmD; Terra Wonsettler, PharmD, MBA; Emma Domico, MS; Andrew Hertler, MD, FACP
This study discusses how Evolent is tackling the rising costs of cancer treatment by actively reducing low-value oncology care through strategic interventions.
This study discusses how Evolent is tackling the rising costs of cancer treatment by actively reducing low-value oncology care through strategic interventions.
This study discusses how Evolent...
04/15/2025
Journal of Clinical Pathways
Research Reports
Total Medical and Pharmacy Costs for Patients With Metastatic Castration-Sensitive Prostate Cancer Initiating Oral Androgen Receptor Pathway Inhibitors in the United States
04/15/2025
Ibrahim Khilfeh, PharmD; Carmine Rossi, PhD; Jill Korsiak; Lilian Diaz, MSc; Bronwyn Moore, BA; Dominic Pilon, MA; Shawn Du, PhD; Lorie Ellis, PhD
In this study, researchers evaluated the total cost of care and components of health care resource use and costs in androgen receptor path­way inhibitor (ARPI)-naïve Medicare-insured patients with metastatic castra­tion-sensitive prostate...
In this study, researchers evaluated the total cost of care and components of health care resource use and costs in androgen receptor path­way inhibitor (ARPI)-naïve Medicare-insured patients with metastatic castra­tion-sensitive prostate...
In this study, researchers...
04/15/2025
Journal of Clinical Pathways
Research Reports
An Oncology Provider-Driven Model to Implement Germline Genetic Testing Among Diverse Patients With Advanced Prostate Cancer
02/18/2025
Lisa Nuccio, MSN, FNP-C; Kirsten Drabek, BS; Neha Hippalgaonkar, MD; Aseem Tiwari, MPH, MD, MBBS; Vivian Pan, MS, PhD; Kent Hoskins, MD; Pamela Ganschow, MD; Tara Maga, PhD, MS; Lara Balay, MS Ed, MS, CGC; Karine Tawagi, MD; Natalie Reizine, MD
In this study, researchers examine the clinical implementation of an oncology-directed model of delivering guideline-concordant germline genetic testing in patients living with and receiving standard-of-care treatment for advanced prostate...
In this study, researchers examine the clinical implementation of an oncology-directed model of delivering guideline-concordant germline genetic testing in patients living with and receiving standard-of-care treatment for advanced prostate...
In this study, researchers...
02/18/2025
Journal of Clinical Pathways
Research Reports
Comparison of Specialty Injection and Infusion Adverse Events Among Hospital Outpatient Settings vs Non-Hospital Outpatient Settings
02/18/2025
Lavanya Raj, MBBS, MS; Gentri Stinson, BSN, MSN, APRN; Jeffrey W. Langsam, DO; Julie DeMacio, RN, BSN
This study analyzes the clinical outcomes associated with Cigna Healthcare’s site-of-care management strategies that redirect injected and infused specialty medications from high-cost hospital outpatient setting or out-of-network providers to...
This study analyzes the clinical outcomes associated with Cigna Healthcare’s site-of-care management strategies that redirect injected and infused specialty medications from high-cost hospital outpatient setting or out-of-network providers to...
This study analyzes the clinical...
02/18/2025
Journal of Clinical Pathways

Conference Coverage

Conference Coverage
BRCA Variants in Patients With Ovarian Cancer and the Risk of Adverse Reactions
06/10/2022
Marta Rybczynski
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at...
06/10/2022
Journal of Clinical Pathways
Conference Coverage
Factors Predicting the Likelihood of Undergoing Biomarker Testing in Ovarian Cancer
06/08/2022
Marta Rybczynski
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented...
06/08/2022
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting
12/07/2021
Janelle Bradley
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Recent Advancements in Biomarker Testing and Therapeutic Strategies in Oncology
05/03/2021
05/03/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
04/07/2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker...
04/07/2021
Journal of Clinical Pathways
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
02/03/2021
02/03/2021
Journal of Clinical Pathways
Conference Coverage
Community-Engaged Strategies Reduce Cancer Care Delays and Advance Health Equity
03/27/2026
Hannah Musick
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
Targeted Education Improves Cancer Pain Management in Community Hospitals
03/27/2026
Grace Taylor, MS, MA
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
SEER Analysis Highlights Risk Factors for Advanced DLBCL at Diagnosis
03/27/2026
Grace Taylor, MS, MA
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis, identifying key demographic and clinical risk factors to guide targeted screening and earlier...
A large SEER-based analysis...
03/27/2026
Journal of Clinical Pathways
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways
News
Lenalidomide Before Apheresis Enhances CAR T-Cell Fitness in Newly Diagnosed Multiple Myeloma
12/19/2025
Grace Taylor, MS, MA
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide significantly improved T-cell fitness and pharmacodynamic activity of idecabtagene vicleucel (ide-cel) in newly diagnosed multiple myeloma (NDMM), according to a KarMMa-2 cross-cohort analysis.
Pre-apheresis lenalidomide...
12/19/2025
Journal of Clinical Pathways
Conference Coverage
High-Risk Features Predict Early Relapse After Cilta-Cel Therapy in Relapsed/Refractory Multiple Myeloma
12/18/2025
Grace Taylor, MS, MA
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver high response rates in RRMM, yet early relapse remains a critical challenge. A multicenter analysis across 15 US academic institutions evaluated high-risk disease biology to identify predictors of suboptimal...
Cilta-cel continues to deliver...
12/18/2025
Journal of Clinical Pathways
Conference Coverage
Intensive Isa-VRDc Regimen Shows Strong Progression-Free Survival in Double-Hit Myeloma
12/17/2025
Hannah Musick
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen achieved an 88% 18-month progression-free survival rate in newly diagnosed, double-hit multiple myeloma patients in the UK RADAR trial, signaling strong early efficacy in this ultra-high-risk population.
An intensified Isa-VRDc regimen...
12/17/2025
Journal of Clinical Pathways
Conference Coverage
Breakthrough Advances in Immunotherapy Transform Care in Leukemia, Lymphoma, and Myeloma
12/17/2025
Grace Taylor, MS, MA
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements across leukemia, lymphoma, and myeloma are reshaping treatment pathways, demonstrating deeper responses, improved survival, and expanding earlier-line options for patients.
Immunotherapy advancements...
12/17/2025
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use